Hope for high-risk chronic lymphocytic leukemia relapsing after allogeneic stem-cell transplantation

Journal of Clinical Oncology

Volumn 33, Issue 14, 2015, Pages 1527-1529

  Montserrat, Emili ^a   Dreger, Peter ^b,c  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c European Society for Blood and Marrow Transplantation   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; IBRUTINIB; IDELALISIB; MONOCLONAL ANTIBODY; PROTEIN P53; RITUXIMAB; ANTINEOPLASTIC AGENT; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; EDITORIAL; GENE MUTATION; HUMAN; LEUKEMIA CELL; LEUKEMIA RELAPSE; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; SALVAGE THERAPY; FEMALE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; PYRAZOLES; PYRIMIDINES; STEM CELL TRANSPLANTATION;

EID: 84933503999     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.3282     Document Type: Editorial

References (20)

1. Michallet M, Corront B, Hollard D, et al: Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: 17 cases - Report from the EBMTG. Bone Marrow Transpl 7:275-279, 1991
2. Sorror ML, Storer BE, Sandmaier BM, et al: Five-year follow-up of patients with advanced chronic lymphocytic leukemia with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 26:4912-4920, 2008
3. Brown JR, Kim HT, Armand P, et al: Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: Prognostic model to predict outcome. Leukemia 27:362-369, 2013
4. Herth I, Dietrich S, Benner A, et al: The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: A retrospective donor versus no donor comparison. Ann Oncol 25:200-206, 2014
5. Schetelig J, Thiede C, Bornhauser M, et al: Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: The Cooperative German Transplant Study Group. J Clin Oncol 21:2747-27535, 2003
6. Richardson SE, Khan I, Rawstron A, et al: Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. Br J Haematol 160:640-648, 2013
7. Dreger P, Schetelig J, Andersen N, et al: Managing high-risk chronic lymphocytic leukemia during transition to a new treatment era: Stem cell transplantation or novel agents? A position statement of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT). Blood 124:3841-3849, 2014
8. Dreger P, Döhner H, Ritgen M, et al: Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: Long-term clinical and MRD results of the GCLLSG CLL3X trial. Blood 116:2438-2447, 2010
9. Moreno C, Villamor N, Colomer D, et al: Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 23:3433-3438, 2005
10. Rozovski U, Benjamini O, Jain P, et al: Outcomes of patients with chronic lymphocytic leukemia and Richter's transformation after transplantation failure. J Clin Oncol 33:1557-1563, 2015
11. Byrd JC, Jones JJ, Woyach JA, et al: Entering the era of targeted therapy for chronic lymphocytic leukemia: Impact on the practicing clinician. J Clin Oncol 32:3039-3047, 2014
12. O'Brien S, Furman RR, Coutre SE, et al: Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b/2 trial. Lancet Oncol 15:48-58, 2014
13. O'Brien S, Furman RF, Coutre SE, et al: Independent evaluation of ibrutinib efficacy 3 years post initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia. J Clin Oncol 32:325s, 2014 (suppl; abst 7014)
14. Byrd JC, Brown JR, O'Brien S, et al: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371:213-223, 2014
15. Furman RR, Sharman JP, Coutre SE, et al: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370:997-1007, 2014
16. Seymour JF, Davids MS, Pagel JM, et al: ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control. J Clin Oncol 32:5s, 2014 (suppl; abst 7015)
17. Strati P, Keating MJ, O'Brien SM, et al: Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica 99:1350-1355, 2014
18. Pettitt AR, Jackson R, Carruthers S, et al: Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: Final results of the National Cancer Res Institute CLL206 Trial. J Clin Oncol 30:1647-1655, 2012
19. Coutre SA, O'Brien S, Byrd JC, et al: Safety and efficacy of ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who have undergone prior allogeneic stem cell transplant. Blood 124:4697, 2014
20. Ryan CR, Logan AC, Rezvani A, et al: Ibrutinib treatment of relapsed CLL following allogeneic transplantation: Sustained disease response and promising donor immune modulation. Blood 124:1186, 2014